Acetohexamide

Acetohexamide is an orally active first-generation sulfonylurea agent used in research related to type 2 diabetes and cancer. Acetohexamide exerts reductase activity in human erythrocytes. Acetohexamide stimulates the pancreas to secrete insulin. Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas. Acetohexamide can inhibit the formation of circular chemorepellent induced defects (CCIDs) in lymphendothelial cell (LEC) monolayers. Acetohexamide inhibits markers of epithelial-to-mesenchymal-transition and migration. Acetohexamide suppresses the synthesis of 12(S)-HETE. Acetohexamide can potentiate hypoglycaemic action^[1][2][3][4]. In Vitro:Acetohexamide (0.5 mM) results in reductase activity in human erythrocytes^[2].
Acetohexamide (40 μM, 4 h) inhibits CCID formation dose-dependently^[3].
Acetohexamide (20-60 μM) inhibits 12(S)-HETE synthesis in an ALOX12-expressing MCF-7 clone^[3].
Acetohexamide (60 μM, 20 min) strongly inhibits 12(S)-HETE-induced phosphorylation of MLC2^[3]. In Vivo:Acetohexamide (Compound AH) (100 mg/kg suspended in water, p.o., single dose) potentiates the hypoglycaemic action in combination with Phenylbutazone (PBZ) in rabbit model^[4].